Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 7.094M
March 31, 2026 -19.22M
December 31, 2025 -51.31M
September 30, 2025 48.71M
June 30, 2025 -30.61M
March 31, 2025 37.32M
December 31, 2024 -12.64M
September 30, 2024 -77.01M
June 30, 2024 -48.59M
March 31, 2024 -51.62M
December 31, 2023 -65.98M
September 30, 2023 34.63M
June 30, 2023 60.30M
March 31, 2023 239.78M
December 31, 2022 -48.76M
September 30, 2022 -82.23M
June 30, 2022 -15.68M
March 31, 2022 -69.99M
December 31, 2021 76.13M
September 30, 2021 -5.704M
June 30, 2021 -80.89M
March 31, 2021 -71.44M
December 31, 2020 49.34M
September 30, 2020 -11.30M
June 30, 2020 -108.18M
Date Value
March 31, 2020 35.44M
December 31, 2019 19.44M
September 30, 2019 -8.355M
June 30, 2019 -65.76M
March 31, 2019 -103.25M
December 31, 2018 34.33M
September 30, 2018 25.34M
June 30, 2018 -422.14M
March 31, 2018 -51.01M
December 31, 2017 -19.13M
September 30, 2017 -21.16M
June 30, 2017 -25.36M
March 31, 2017 -20.76M
December 31, 2016 -13.64M
September 30, 2016 -10.35M
June 30, 2016 -1.322M
March 31, 2016 -10.65M
December 31, 2015 -15.93M
September 30, 2015 -5.698M
June 30, 2015 -6.54M
March 31, 2015 -11.12M
December 31, 2014 -8.684M
September 30, 2014 -0.973M
June 30, 2014 6.399M
March 31, 2014 -1.629M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Indivior Pharmaceuticals, Inc. -7.942M
Pfizer Inc. 2.106B
Amphastar Pharmaceuticals, Inc. 44.87M
Collegium Pharmaceutical, Inc. -502.59M
Bristol Myers Squibb Co. -1.614B